You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Hu3F8

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 1, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)

Active, not recruiting
  • Neuroblastoma
  • High-Risk
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 14, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Neuroblastoma Trial in New York (Humanized 3F8 Monoclonal Antibody (Hu3F8))

Active, not recruiting
  • Neuroblastoma
  • Humanized 3F8 Monoclonal Antibody (Hu3F8)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 24, 2021

Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)

Active, not recruiting
  • Neuroblastoma (NB)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 19, 2021

Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)

Completed
  • Neuroblastoma
  • 3F8 Monoclonal Antibody Combined with Interleukin-2
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 26, 2021

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Melanoma, Neuroblastoma, Sarcoma Trial in New York (124I-Humanized 3F8)

Active, not recruiting
  • Melanoma
  • +2 more
  • 124I-Humanized 3F8
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 1, 2022

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Neoplasm
  • (no location specified)
Apr 24, 2023

Mycosis Fungoides, Recurrent Mycosis Fungoides, Recurrent Mycosis Fungoides and Sezary Syndrome Trial in United States

Recruiting
  • Mycosis Fungoides
  • +11 more
  • Biospecimen Collection
  • +5 more
  • Duarte, California
  • +12 more
Jan 7, 2023

Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8 Trial in Chicago (procedure,

Not yet recruiting
  • Prostate Adenocarcinoma
  • +3 more
  • Biopsy of Prostate
  • +6 more
  • Chicago, Illinois
    Northwestern University
May 9, 2023

Non Hodgkin Lymphoma Trial in Australia, United Kingdom, United States (Magrolimab, Rituximab, Gemcitabine)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Birmingham, Alabama
  • +19 more
Dec 8, 2022

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
Has Results
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

Glioblastoma Trial in Rochester (radiation, procedure, drug, other)

Recruiting
  • Glioblastoma
  • Accelerated Hypofractionated Radiation Therapy
  • +8 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Mar 24, 2023

Exudative Macular Degeneration, Retinal Hemorrhage Trial in United Kingdom (Ranibizumab, C3F8 Gas, tPA)

Completed
  • Exudative Macular Degeneration
  • Retinal Hemorrhage
  • Maidstone, Kent, United Kingdom
  • +4 more
Jul 10, 2020

Astigmatism, Myopia Trial in Edinburgh, Oakwood, Heckmondwike (Lens A (Test), Lens B (control))

Active, not recruiting
  • Astigmatism
  • Myopia
  • Lens A (Test)
  • Lens B (control)
  • Edinburgh, Edinburg, United Kingdom
  • +2 more
May 4, 2022

Lymphoma Trial in Worldwide (bleomycin sulfate, filgrastim, pegfilgrastim)

Completed
  • Lymphoma
  • bleomycin sulfate
  • +12 more
  • Garran, Australian Capital Territory, Australia
  • +139 more
Dec 19, 2022

Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)

Completed
  • Neuroblastoma
  • beta-glucan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Smoking Cessation, Nicotine Addiction, Schizophrenia Trial in Baltimore (active F8-coil delivered rTMS, active H-coil delivered

Recruiting
  • Smoking Cessation
  • +2 more
  • active F8-coil delivered rTMS
  • active H-coil delivered rTMS
  • Baltimore, Maryland
    University of Maryland, Baltimore
Nov 15, 2022

Retinal Detachment Trial (Pars plana vitrectomy, Pars plana vitrectomy with scleral buckle, Sulfur hexafluoride gas tamponade)

Not yet recruiting
  • Retinal Detachment
  • Pars plana vitrectomy
  • +3 more
  • (no location specified)
May 16, 2023